{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:11:29Z","timestamp":1778778689099,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","award":["18-015-00133"],"award-info":[{"award-number":["18-015-00133"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","award":["AAAA-A17-117020210024-8"],"award-info":[{"award-number":["AAAA-A17-117020210024-8"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","award":["AAAA-A17-117020210021-7"],"award-info":[{"award-number":["AAAA-A17-117020210021-7"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejpb.2021.03.006","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T23:30:38Z","timestamp":1616196638000},"page":"92-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Pronounced therapeutic potential of oligonucleotides fixed on inorganic nanoparticles against highly pathogenic H5N1 influenza A virus in vivo"],"prefix":"10.1016","volume":"162","author":[{"given":"Asya","family":"Levina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Repkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadezhda","family":"Shikina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinfer","family":"Ismagilov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxim","family":"Kupryushkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pavlova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Mazurkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitrii","family":"Pyshnyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Zarytova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2021.03.006_b0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12033-013-9670-8","article-title":"Cross-protective effect of antisense oligonucleotide developed against the common 3\u2032 NCR of influenza A virus genome","volume":"55","author":"Kumar","year":"2013","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.ejpb.2021.03.006_b0010","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2174\/1566524015666150630124300","article-title":"Taming influenza virus: role of antisense technology","volume":"15","author":"Jain","year":"2015","journal-title":"Curr. Mol. Med."},{"issue":"1","key":"10.1016\/j.ejpb.2021.03.006_b0015","first-page":"49","article-title":"The treatment of influenza with antiviral drugs","volume":"168","author":"Stiver","year":"2003","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.ejpb.2021.03.006_b0020","unstructured":"A. Hay, Antiviral drug resistance, in: D. Richman (Ed.), John Willey and Sons Ltd, Chichester, UK, 1996, pp. 44\u201358."},{"key":"10.1016\/j.ejpb.2021.03.006_b0025","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1016\/S0040-4039(01)89794-X","article-title":"Synthesis of ribonucleosides and diribonucleoside phosphates containing 2-chloroethylamine and nitrogen mustard residues","volume":"37","author":"Belikova","year":"1967","journal-title":"Tetrahedron Lett."},{"issue":"1","key":"10.1016\/j.ejpb.2021.03.006_b0030","first-page":"1019","article-title":"History and properties of morpholino antisense oligos","volume":"3","author":"Sommerton","year":"2016","journal-title":"J. Drug. Discov. Develop. Deliv."},{"key":"10.1016\/j.ejpb.2021.03.006_b0035","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamechnik","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2021.03.006_b0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2015.04.012","article-title":"DNA and RNA derivatives to optimize distribution and delivery","volume":"87","author":"Wickstrom","year":"2015","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.ejpb.2021.03.006_b0045","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.addr.2015.02.008","article-title":"Delivery of therapeutic oligonucleotides with cell-penetrating peptides","volume":"87","author":"Boisgu\u00e9rin","year":"2015","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.ejpb.2021.03.006_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1166\/jbn.2016.2122","article-title":"Inorganic nanomaterials as carriers for drug delivery","volume":"12","author":"Chen","year":"2016","journal-title":"Biomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2021.03.006_b0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.addr.2015.04.005","article-title":"Cellular uptake and intracellular trafficking of oligonucleotides","volume":"86","author":"Juliano","year":"2015","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.ejpb.2021.03.006_b0060","first-page":"1","article-title":"Advancements in nucleic acid-based therapeutics against respiratory viral infections","volume":"8","author":"Asha","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejpb.2021.03.006_b0065","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1166\/jnn.2012.5190","article-title":"Nanocomposites consisting of titanium dioxide nanoparticles and oligonucleotides","volume":"12","author":"Levina","year":"2012","journal-title":"J. Nanosci. Nanotech."},{"key":"10.1016\/j.ejpb.2021.03.006_b0070","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1109\/TNANO.2016.2516561","article-title":"Nanoparticle-mediated nonviral DNA delivery for effective inhibition of influenza A viruses in cells","volume":"15","author":"Levina","year":"2016","journal-title":"IEEE Trans. Nanotechnol."},{"key":"10.1016\/j.ejpb.2021.03.006_b0075","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1166\/jnn.2017.13916","article-title":"Stabilization of TiO2 sols dispersity at physiological conditions and decrease their cytotoxic properties","volume":"17","author":"Shikina","year":"2017","journal-title":"J. Nanosci. Nanotech."},{"key":"10.1016\/j.ejpb.2021.03.006_b0080","doi-asserted-by":"crossref","unstructured":"A.S. Levina, Z.R. Ismagilova, M.N. Repkova, N.V. Shikina, S.I. Baiborodin, N.V. Shatskaia, et al., TiO2-DNA nanocomposites capable of penetrating into cells, Bioorgan. Khim. 39(1) (2013) 87\u201398. DOI:0.1134\/s1068162013010068.","DOI":"10.1134\/S1068162013010068"},{"key":"10.1016\/j.ejpb.2021.03.006_b0085","doi-asserted-by":"crossref","first-page":"A46","DOI":"10.1016\/j.antiviral.2008.01.092","article-title":"Check of antiviral activity of nanocomposites, which contained oligonucleotides for direct splitting viral genome of influenza virus type A","volume":"78","author":"Pletnev","year":"2008","journal-title":"Antiviral. Res."},{"key":"10.1016\/j.ejpb.2021.03.006_b0090","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ijantimicag.2017.01.026","article-title":"Efficient inhibition of influenza A viral replication in cells by deoxyribozymes delivered by nanocomposites","volume":"49","author":"Repkova","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejpb.2021.03.006_b0095","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/srep00756","article-title":"High-performance method for specific effect on nucleic acids in cells using TiO2~DNA nanocomposites","volume":"2","author":"Levina","year":"2012","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2021.03.006_b0100","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3762\/bjnano.7.108","article-title":"High antiviral effect of TiO2\u00b7PL\u2013DNA nanocomposites targeted to conservative regions of (\u2212)RNA and (+)RNA of influenza A virus in cell culture","volume":"7","author":"Levina","year":"2016","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.ejpb.2021.03.006_b0105","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijantimicag.2015.03.004","article-title":"Knockdown of different influenza A virus subtypes in cell culture by a single antisense oligodeoxyribonucleotide","volume":"46","author":"Levina","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejpb.2021.03.006_b0110","unstructured":"D.A. Stetsenko, M.S. Kupryushkin, D.V. Pyshnyi, Modified oligonucleotides and methods for their synthesis, Patent application WO2016\/028187 A1 2014; priority from 22.08.2014."},{"key":"10.1016\/j.ejpb.2021.03.006_b0115","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1099\/vir.0.83449-0","article-title":"Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus","volume":"89","author":"Gabriel","year":"2008","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ejpb.2021.03.006_b0120","doi-asserted-by":"crossref","unstructured":"L. Sachs, Applied statistics. A Handbook of Techniques, Springer\u2010Verlag, New York-Heidelberg-Berlin, 1982.","DOI":"10.1007\/978-1-4684-0123-3"},{"key":"10.1016\/j.ejpb.2021.03.006_b0125","unstructured":"Guide for the care and use of laboratory animals, National Academy Press, Washington DC, 1996."},{"key":"10.1016\/j.ejpb.2021.03.006_b0130","first-page":"241","article-title":"The effect of chemical treatment conditions of titanium dioxide sols on their dispersion and cytotoxic properties","volume":"27","author":"Ismagilov","year":"2012","journal-title":"Chem. Eng. Trans."},{"issue":"8","key":"10.1016\/j.ejpb.2021.03.006_b0135","article-title":"Infection of inbred BALB\/c and C57BL\/6 and outbred Institute of Cancer Research mice with the emerging H7N9 avian influenza virus","volume":"2","author":"Zhu","year":"2013","journal-title":"Emerg. Microbes. Infect."},{"key":"10.1016\/j.ejpb.2021.03.006_b0140","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3390\/v6020573","article-title":"Pretreatment of mice with oligonucleotide prop5 protects them from influenza virus infections","volume":"6","author":"Li","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.ejpb.2021.03.006_b0145","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jgm.1558","article-title":"Inhibition of highly pathogenic avian H5N1 influenza virus propagation by RNA oligonucleotides targeting the PB2 gene in combination with celecoxib","volume":"13","author":"Jin","year":"2011","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ejpb.2021.03.006_b0150","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1126\/science.1125559","article-title":"Oligonucleotide-modified gold nanoparticles for intracellular gene regulation","volume":"312","author":"Rosi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2021.03.006_b0155","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.1073\/pnas.0402486101","article-title":"Inhibition of influenza virus production in virus-infected mice by RNA interference","volume":"101","author":"Ge","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2021.03.006_b0160","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/135965350801300112","article-title":"In vitro and in vivo protection against the highly pathogenic H5N1 influenza virus by an antisense phosphorothioate oligonucleotide","volume":"13","author":"Duan","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejpb.2021.03.006_b0165","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00705-008-0262-z","article-title":"Inhibition of influenza A virus replication by short double-stranded oligodeoxynucleotides","volume":"154","author":"Kwok","year":"2009","journal-title":"Arch. Virol."},{"key":"10.1016\/j.ejpb.2021.03.006_b0170","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2147\/DDDT.S195481","article-title":"Transportan-derived cell-penetrating peptide delivers siRNA to inhibit replication of influenza virus in vivo","volume":"13","author":"Zhang","year":"2019","journal-title":"Drug. Des. Devel. Ther."},{"issue":"4","key":"10.1016\/j.ejpb.2021.03.006_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174523","article-title":"In vivo inhibition of influenza A virus replication by RNA interference targeting the PB2 subunit via intratracheal delivery","volume":"12","author":"Huang","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2021.03.006_b0180","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1006\/bbrc.2000.3924","article-title":"Inhibitory effects of an antisense oligonucleotide in an experimentally infected mouse model of influenza A virus","volume":"279","author":"Mizuta","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.ejpb.2021.03.006_b0185","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/nar\/28.2.582","article-title":"Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides","volume":"28","author":"Lorenz","year":"2000","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.ejpb.2021.03.006_b0190","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1021\/mp900093r","article-title":"Biological barriers to therapy with antisense and siRNA oligonucleotides","volume":"6","author":"Juliano","year":"2009","journal-title":"Mol. Pharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121000722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121000722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:26:47Z","timestamp":1778776007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641121000722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":38,"alternative-id":["S0939641121000722"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.03.006","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pronounced therapeutic potential of oligonucleotides fixed on inorganic nanoparticles against highly pathogenic H5N1 influenza A virus in vivo","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}